12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

ACP-501 regulatory update

The European Commission granted Orphan Drug designation to AlphaCore's ACP-501 to treat familial lecithin-cholesterol acyltransferase (LCAT)...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >